[go: up one dir, main page]

WO2021095840A1 - Procédés de traitement de maladies et de troubles associés à lsd1 avec des inhibiteurs de lsd1 - Google Patents

Procédés de traitement de maladies et de troubles associés à lsd1 avec des inhibiteurs de lsd1 Download PDF

Info

Publication number
WO2021095840A1
WO2021095840A1 PCT/JP2020/042410 JP2020042410W WO2021095840A1 WO 2021095840 A1 WO2021095840 A1 WO 2021095840A1 JP 2020042410 W JP2020042410 W JP 2020042410W WO 2021095840 A1 WO2021095840 A1 WO 2021095840A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
phenyl
week
salt
aminopyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/042410
Other languages
English (en)
Inventor
Hiroko HITOTSUMACHI
Takumitsu Machida
Masaki Yamada
Harold Keer
Aram Oganesian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Astex Pharmaceuticals Inc
Original Assignee
Taiho Pharmaceutical Co Ltd
Astex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd, Astex Pharmaceuticals Inc filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP2022527859A priority Critical patent/JP7492002B2/ja
Priority to MX2022005812A priority patent/MX2022005812A/es
Priority to KR1020227019783A priority patent/KR20220113390A/ko
Priority to EP20886658.2A priority patent/EP4058018A4/fr
Priority to BR112022008020A priority patent/BR112022008020A2/pt
Priority to CA3158442A priority patent/CA3158442A1/fr
Priority to AU2020382379A priority patent/AU2020382379B2/en
Priority to CN202080079021.0A priority patent/CN114828844A/zh
Priority to PH1/2022/551169A priority patent/PH12022551169A1/en
Priority to US17/775,800 priority patent/US20220387384A1/en
Publication of WO2021095840A1 publication Critical patent/WO2021095840A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to methods of treating a patient with an LSD1-related disease or disorder with an LSD1 inhibitor according to one or more specific dosing regimens. Aspects of the invention also include LSD1 inhibitors, as well as methods of making such LSD1 inhibitors and compositions, including pharmaceutical compositions, comprising such LSD1 inhibitors, and their various uses.
  • Histone methylation modification is one of the epigenetic mechanisms that regulates gene expression. Histone methylation modification regulates various processes including, but not limited to, cellular maintenance, growth, and differentiation.
  • LSD1 (KDM1A), one of the enzymes that regulates histone methylation modification, is an FAD (flavin adenine dinucleotide)-dependent histone demethylase, and mainly demethylates the lysine residue at position 4 (K4) and the lysine residue at position 9 (K9) on histone H3 (Non-patent Literature (NPL) 1).
  • FAD farnesode demethylase
  • NPL Non-patent Literature
  • LSD1 inhibitory drugs are expected to provide effective therapeutic means based on novel mechanisms to treat intractable cancers, for which no therapeutic methods currently exist.
  • LSD1 which is involved in neuron programs and functions, can also possibly serve as a target in the treatment of diseases other than cancers, such as Alzheimer’s disease, Huntington’s disease, Rett syndrome, and other cranial nerve diseases (NPL 2); Herpesvirus infections, in which LSD1 function has been implicated (NPL 5); and sickle cell diseases (NPL 6).
  • diseases other than cancers such as Alzheimer’s disease, Huntington’s disease, Rett syndrome, and other cranial nerve diseases (NPL 2); Herpesvirus infections, in which LSD1 function has been implicated (NPL 5); and sickle cell diseases (NPL 6).
  • LSD1 inhibitors were administered in clinical trials. LSD1 inhibitors are categorized into two groups: LSD1 inhibitors that covalently bind to FAD, and LSD1 inhibitors that compete with the substrate histone H3. For the former covalent-type, the most typical administration schedule was continuous daily administration. For example, the covalent-type LSD1 inhibitor GSK-2879552 (GlaxoSmithKline PLC) was administered continuously daily for their Phase 1 study of acute myeloid leukemia and Phase 1/2 study of myelodysplastic syndromes (NPL7).
  • GSK-2879552 GaxoSmithKline PLC
  • Another covalent-type LSD1 inhibitor INCB-59872 (Incyte Corp) was administered continuously daily in a 21-day cycle for their Phase 1/2 study of solid tumors, non-small cell lung cancer (NSCLC) and colon cancer, and administered continuously daily for a Phase 1 study of sickle cell disease (NPL8).
  • the other typical administration schedules involved intermittent administration at 1 day or 2 day intervals.
  • another covalent-type LSD1 inhibitor ORY-1001/ RO7051790 (Oryzon Genomics) was administered for a Phase 1/2a study of acute myeloid leukemia in a 4-week administration schedule consisting of 4 cycles of 5 days continuous administration, followed by a two day interval period (NPL9).
  • Compound A The compound 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile (referred to herein as Compound A) has been known as a potent LSD1 inhibitor (PL 1). This compound is an LSD1 inhibitor that competes with the substrate histone H3. No administration schedules or dosage regimens for Compound A have been described in the art.
  • aspects of the invention include methods of treating an LSD1-related disease or disorder in a patient in need by administering an effective amount of Compound A utilizing a specific administration schedule.
  • the present inventors have discovered that continuous administration of Compound A shows anti-tumor effects, but can at the same time result in one or more unfavorable events or side-effects, such as myelosuppression and/or body weight loss.
  • the inventors conducted extensive studies, and consequently discovered that continuous administration of Compound A for a specific period of time, followed by a resting period having a specific length of time without administering Compound A, achieved an anti-tumor effect with fewer unfavorable events and side-effects.
  • the present invention is based on this unexpected and surprising discovery.
  • a method of treating a patient with an LSD1-related disease or disorder includes administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule of continuous, daily dosing for one week followed by a resting period of one week.
  • a method of treating a patient with an LSD1-related disease or disorder includes administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule of continuous, daily dosing for two weeks followed by a resting period of one week.
  • FIG. 1A is a graph illustrating the number of platelets in a sample of Group I subject to a 1-week ON+1-week OFF dosing regimen.
  • the left blank bar shows values from Test Compound A 0 mg/kg (vehicle as control) treated animals, and the right filled bar shows values from Test Compound A 16mg/kg treated animals.
  • the “Week” columns “1”, “2”, “3” and “4” show the values from the samples obtained on Day 8, Day 15, Day 22 and Day 29, respectively. Error bars: standard deviations from averages, NE: not examined
  • FIG. 1B is a graph illustrating the number of neutrophils in a sample of Group I subject to a 1-week ON+1-week OFF dosing regimen.
  • FIG. 2A is a graph illustrating the number of platelets in a sample of Group II subject to a 2-week ON+1-week OFF dosing regimen.
  • the left blank bar shows values from Test Compound A 0mg/kg (vehicle as control) treated animals, and the right filled bar shows values from Test Compound A 16mg/kg treated animals.
  • FIG. 2B is a graph illustrating the number of neutrophils in a sample of Group II subject to a 2-week ON+1-week OFF dosing regimen.
  • the left blank bar shows values from Test Compound A 0mg/kg (vehicle as control) treated animals, and the right filled bar shows values from Test Compound A 16mg/kg treated animals.
  • the “Week” columns “2” and “3” shows the values from the samples obtained on Day 15 and Day 22, respectively. Error bars: standard deviations from averages.
  • FIG. 3 is a photograph of abnormal neutrophil-lineage myelocytes (indicated by the arrow).
  • FIG. 4A is a photograph of abnormal megakaryocytes.
  • FIG. 4B is a photograph of abnormal megakaryocytes.
  • FIG. 5 is a graph showing tumor volume of the control group, the Continuous group, the Group I group and the Group II group. ***: p ⁇ 0.001, Dunnett t-test, N.S.: Not Significant, Aspin-Welch t-test, Error bar: SE: Standard Error
  • FIG. 6 is a graph showing body weight change of the control group, the Continuous group, the Group I group and the Group II group. Error bar: SE: Standard Error
  • aspects of the invention include methods of treating a disease or disorder characterized by expression of LSD1 by administering an antitumor agent on an administration schedule including a period of continuous, daily dosing followed by a specific resting period with no dosing.
  • a method of treating a disease or disorder characterized by the expression of LSD1 includes administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile (“Compound A”) or a salt thereof to a patient in need.
  • Compound A 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile
  • the methods involve administering Compound A or a salt thereof on an administration schedule comprising continuous, daily dosing for one week, followed by a resting period of one week. In some embodiments, the methods involve administering Compound A or a salt thereof on an administration schedule comprising continuous, daily dosing for a period of two weeks, followed by a resting period of one week.
  • Compound A is described as Example compound 37 of PCT Publication No. WO2017/090756, the disclosure of which is incorporated by reference herein in its entirety.
  • Compound A can be produced by any known methods in the art, including, but not limited to, those methods described in PCT Publication No. WO2017/090756, the disclosure of which is incorporated by reference herein in its entirety.
  • novel methods of treatment described herein exhibit an effect of reducing one or more unfavorable observations, such as side effects, adverse reactions or adverse events, for example, weight loss and/or myelosuppression, while achieving an antitumor effect.
  • the antitumor agent is administered for a one or two week period of continuous administration, followed by a resting period having a duration of one week.
  • the administration schedule described herein comprising a one week period of continuous administration followed by a resting period of one week demonstrated advantages in terms of reduction in one or more unfavorable events or side-effects.
  • the administration schedule described herein comprising a two week period of continuous administration followed by a resting period of one week demonstrated advantages in terms of drug safety, including reduced toxicity.
  • the administration schedule is not particularly limited, as long as it includes a one or two week period of continuous administration, followed by a resting period of one week.
  • a two week (14 day) administration schedule consisting of one week (7 days) of continuous administration followed by a one week (7 day) resting period is defined as one (1) cycle
  • the cycle can be performed once or repeated twice or more to treat the disease or disorder. That is, the administration can be carried out in one cycle, or more than one cycle, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 cycles or more of a specific administration schedule. In some embodiments, the administration can be carried out in long-periods comprising several cycles.
  • the administration can be carried out for a period of 6-months with approximately 13 to 15 cycles of treatment or administration; a 1-year period with approximately 25 or 26 cycles of treatment; a 3-year period with approximately 75 to 100 cycles of treatment or more.
  • a three week (21 day) administration schedule consisting of two weeks (14 days) of administration followed by a one week (7 day) resting period, is defined as one (1) cycle
  • the cycle can be performed once or repeated two or more times. That is, the administration can be carried out in one cycle, or more than one cycle, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 cycles, or more of the administration schedule.
  • the administration can be carried out in more cycles.
  • the administration can be carried out for a period of 6 months with approximately 10 cycles; a 1-year period with approximately 20 cycles; a 3-year period with approximately 50 to 60 cycles or longer periods of administration with more cycles.
  • the administration schedule of the present invention may include a schedule having a plurality of periods of drug holiday. In one embodiment of an administration schedule having a drug holiday, it is sufficient that the conditions "one or two week continuous administration followed by a resting period of one week" are satisfied in the dosing period before the drug holiday and in the dosing period after the drug holiday.
  • an administration schedule having two periods of drug holiday it is sufficient that the conditions "one or two week continuous administration followed by a resting period of one week " are satisfied in the dosing period before the first period of drug holiday, in the dosing period between the two periods of drug holiday, and in the dosing period after the second period of drug holiday.
  • the period of drug holiday is not particularly limited, and can be suitably set according to the patient’s state, and the like.
  • the period of drug holiday can be within the range of 1 to 35 days.
  • the period of drug holiday can be within the range of 1 to 12 months.
  • Compound A or a salt thereof is administered once or more than once each day. In a preferred embodiment, Compound A or a salt thereof is administered once per day.
  • a typical daily dose of Compound A or salt thereof can be in the range from 100 picograms to 100 milligrams per kilogram of body weight, more typically 10 nanograms to 25 milligrams per kilogram of bodyweight. More typically, a daily dose of Compound A or salt thereof can be in the range from 100 nanograms to 20 milligrams per kilogram of bodyweight although higher or lower doses may be administered where required.
  • the daily dose may be 1 micrograms to 20 milligrams of bodyweight, more typically 10 micrograms to 20 milligrams per kilogram of bodyweight, and more typically 100 micrograms to 20 milligrams per kilogram of bodyweight.
  • Dosages may also be expressed as the amount of drug administered relative to the body surface area of the patient (mg/m 2 ).
  • a typical daily dose of Compound A or salt thereof can be in the range from 3700 pg/m 2 to 3700 mg/m 2 , although higher or lower doses may be administered where required.
  • the daily dose may be 370 ng/m 2 to 925 mg/m 2 , more typically 3700 ng/m 2 to 740 mg/m 2 , although higher or lower doses may be administered where required.
  • 37 micrograms/m 2 to 740 mg/m 2 and more typically 370 micrograms/m 2 to 740 mg/m 2 , or 3700 micrograms/m 2 to 740 mg/m 2 .
  • Compound A or salt thereof of the invention may be administered orally in a range of single doses, for example 0.05 to 3000 mg.
  • the range may be 10 to 1000 mg.
  • Typical examples of doses include 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900 and 1000 mg.
  • the doses may be increased or decreased in a stepwise manner from any dose in the above range (of 0.05 to 3000 mg) in increments/decrements of, for example, 1 mg, 5 mg, 10 mg, 20 mg, or 50 mg.
  • compositions containing Compound A or salts thereof used in the present invention can be formulated in accordance with known techniques. See for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
  • the pharmaceutical compositions can be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, sublingual, ophthalmic, otic, rectal, intra-vaginal, or transdermal administration. Of these, the embodiment in oral administration is preferred.
  • the compositions are intended for parenteral administration, they can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration or for direct delivery into a target organ or tissue by injection, infusion or other means of delivery.
  • the delivery can be by bolus injection, short- term infusion or longer term infusion and can be via passive delivery or through the utilization of a suitable infusion pump or syringe driver.
  • Compound A or a salt thereof used in the present invention may be in the form of crystals. Single crystals and polymorphic crystal mixtures are included within the scope of Compound A or a salt thereof. Such crystals can be produced by crystallization according to a crystallization method known in the art.
  • Compound A or a salt thereof may be a solvate (e.g., a hydrate) or a non-solvate. Any of such forms are included within the scope of the compound of the present invention or a salt thereof.
  • Compounds A labeled with an isotope are also included within the scope of Compound A or a salt thereof used in the present invention.
  • the salts of Compound A used in the present invention refer to common salts used in the field of organic chemistry. Examples of such salts include base addition salts, and acid addition salts.
  • the salts of Compound A are preferably pharmaceutically acceptable salts.
  • base addition salts include alkali metal salts, such as sodium salts and potassium salts; alkaline earth metal salts, such as calcium salts and magnesium salts; ammonium salts; and organic amine salts, such as trimethylamine salts, triethylamine salts, dicyclohexylamine salts, ethanolamine salts, diethanolamine salts, triethanolamine salts, procaine salts, and N,N’-dibenzylethylenediamine salts.
  • alkali metal salts such as sodium salts and potassium salts
  • alkaline earth metal salts such as calcium salts and magnesium salts
  • ammonium salts such as sodium salts and magnesium salts
  • organic amine salts such as trimethylamine salts, triethylamine salts, dicyclohexylamine salts, ethanolamine salts, diethanolamine salts, triethanolamine salts, procaine salts, and N,N’-dibenzylethylenediamine salts.
  • acid addition salts include inorganic acid salts, such as hydrochloride, sulfate, nitrate, phosphate, and perchlorate; organic acid salts, such as acetate, formate, maleate, fumarate, tartrate, citrate, ascorbate, benzoate and trifluoroacetate; and sulfonates such as methanesulfonate, isethionate, benzenesulfonate, and p-toluenesulfonate.
  • inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, and perchlorate
  • organic acid salts such as acetate, formate, maleate, fumarate, tartrate, citrate, ascorbate, benzoate and trifluoroacetate
  • sulfonates such as methanesulfonate, isethionate, benzenesulfonate, and p-toluene
  • One example of a salt of Compound A is benzoic acid salt or benzoate salt.
  • Another example of a salt of Compound A is mesylate, esylate, malate, fumarate or tosylate salt.
  • Compound A or salts thereof used in the present invention are useful as a pharmaceutical preparation for preventing and treating LSD1-related diseases.
  • the administration schedule of the present invention is useful for treating LSD1 related diseases.
  • LSD1-related diseases or disorders or diseases and disorders “characterized by expression and/or activity of LSD1”, which terms are used interchangeably herein, include diseases, the incidence of which can be reduced, and symptoms of which can be remitted, relieved, and/or completely cured by eliminating, suppressing, and/or inhibiting LSD1 function.
  • diseases include, but are not limited to, malignant tumors, etc.
  • the type of malignant tumor to be treated by the Compound A or a salt thereof is not particularly limited.
  • malignant tumors include head and neck cancers, esophagus cancer, gastric cancer, colon cancer, rectum cancer, liver cancer, gallbladder cancer, cholangiocarcinoma, biliary tract cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, renal cancer, bladder cancer, prostate cancer, testicular tumor, osteosarcoma, soft-tissue sarcoma, leukemia, myelodysplastic syndrome, chronic myeloproliferative disease, malignant lymphoma, multiple myeloma, skin cancer, brain tumor, mesothelioma, and the like.
  • Preferable examples include lung cancers (e.g., non-small cell lung cancer and small cell lung cancer), leukemia, and myelodysplastic syndromes. More preferably, examples include lung cancers (non-small-cell lung cancer, small-cell lung cancer, etc.) and leukemia. More preferably, examples include small-cell lung cancer (SCLC) and acute myeloid leukemia (AML).
  • lung cancers e.g., non-small cell lung cancer and small cell lung cancer
  • leukemia e.g., myelodysplastic syndromes. More preferably, examples include lung cancers (non-small-cell lung cancer, small-cell lung cancer, etc.) and leukemia. More preferably, examples include small-cell lung cancer (SCLC) and acute myeloid leukemia (AML).
  • SCLC small-cell lung cancer
  • AML acute myeloid leukemia
  • a pharmaceutical carrier can be added, if required, thereby forming a suitable dosage form according to prevention and treatment purposes.
  • the dosage form include oral preparations, injections, suppositories, ointments, patches, and the like. Of these, oral preparations are preferable.
  • Such dosage forms can be formed by methods conventionally known to persons skilled in the art.
  • various conventional organic or inorganic carrier materials used as preparation materials may be used.
  • such materials can be blended as an excipient, binder, disintegrant, lubricant, or coating agent in solid preparations; or as a solvent, solubilizing agent, suspending agent, isotonizing agent, pH adjuster, buffer, or soothing agent in liquid preparations.
  • pharmaceutical preparation additives such as antiseptics, antioxidants, colorants, taste-masking or flavoring agents, and stabilizers, can also be used, if required.
  • Oral solid preparations are prepared as follows. After an excipient is added optionally with a binder, disintegrant, lubricant, colorant, taste-masking or flavoring agent, etc., to Compound A of the present invention, the resulting mixture is formulated into tablets, coated tablets, granules, powders, capsules, or the like by methods known in the art.
  • excipients include lactose, sucrose, D-mannitol, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, and silicic acid anhydride.
  • binders include water, ethanol, 1-propanol, 2-propanol, simple syrup, liquid glucose, liquid ⁇ -starch, liquid gelatin, D-mannitol, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, methyl cellulose, ethyl cellulose, shellac, calcium phosphate, polyvinylpyrrolidone, and the like.
  • disintegrators include dry starch, sodium alginate, powdered agar, sodium hydrogen carbonate, calcium carbonate, sodium lauryl sulfate, stearic acid monoglyceride, lactose, and the like.
  • lubricants include purified talc, sodium stearate, magnesium stearate, borax, polyethylene glycol, and the like.
  • colorants include titanium oxide, iron oxide, and the like.
  • taste-masking or flavoring agents include sucrose, bitter orange peel, citric acid, tartaric acid, and the like.
  • a taste-masking agent When a liquid preparation for oral administration is prepared, a taste-masking agent, a buffer, a stabilizer, a flavoring agent, and the like may be added to Compound A; and the resulting mixture may be formulated into an oral liquid preparation, syrup, elixir, etc., according to methods known in the art.
  • Examples of taste-masking or flavoring agents may be the same as those mentioned above.
  • Examples of buffers include sodium citrate and the like.
  • Examples of the stabilizer include tragacanth, gum arabic, gelatin, and the like.
  • these preparations for oral administration may be coated according to methods known in the art with an enteric coating or other coating for the purpose of, for example, persistence of effects.
  • Examples of such coating agents include hydroxypropyl methylcellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, polyoxyethylene glycol, and Tween 80 (registered trademark).
  • a pH adjuster When an injection is prepared, a pH adjuster, a buffer, a stabilizer, an isotonizing agent, a topical anesthetic, and the like may be added to Compound A; and the resulting mixture may be formulated into subcutaneous, intramuscular, and intravenous injections according to an ordinary method.
  • Examples of usable pH adjusters and buffers include sodium citrate, sodium acetate, sodium phosphate, and the like.
  • examples of usable stabilizers include sodium pyrosulfite, EDTA, thioglycolic acid, thiolactic acid, and the like.
  • Examples of usable topical anesthetics include procaine hydrochloride, lidocaine hydrochloride, and the like.
  • Examples of usable isotonizing agents include sodium chloride, glucose, D-mannitol, glycerin, and the like.
  • the amount of Compound A to be incorporated in each of such dosage unit forms used in the present invention depends on the condition of the patient to whom Compound A is administered, the dosage form, etc.
  • the amount of Compound A is preferably 0.05 to 1000 mg, 0.01 to 500 mg, and 1 to 1000 mg, respectively, per dosage unit form.
  • the daily dose of the medicine in such a dosage form depends on the condition, body weight, age, gender, etc., of the patient, and cannot be generalized.
  • the daily dose of Compound A for an adult may be usually 0.05 to 5000 mg, and preferably 0.1 to 1000 mg; and is preferably administered in one dose, or in two to three divided doses, per day.
  • the administration schedule of the present invention can be applied for a single administration of Compound A or salts thereof.
  • the administration schedule of the present invention can be applied for an administration of Compound A or salts in combination with other drug(s).
  • Compound A or salts can be administered on the same day or at the same timing for those of such other drug(s), or, Compound A can be administered on a different day or at a different timing for those of such other drug(s).
  • Such other drug(s) can be administered continuously, sporadically or intermittently during the administration schedule of Compound A or salts thereof of the present invention.
  • Compound A or a salt thereof in combination with one or more other antitumor agents enhances the antitumor effect.
  • the present invention encompasses an administration schedule using Compound A or a salt in such a combinatory manner.
  • the form of a combination of Compound A or a salt thereof and one or more other antitumor agents may be a single preparation (i.e., a combination drug) or two or more separate preparations to be administered in combination.
  • the antitumor effect can be evaluated as, for example, reduced tumor volume, tumor growth stasis, or prolonged survival time.
  • an administration schedule includes administering an antitumor formulation comprising a combination of Compound A or a salt thereof and one or more other antitumor agents.
  • an administration schedule includes administering an antitumor effect potentiator for an antitumor agent, the potentiator comprising Compound A or a salt thereof as an active ingredient.
  • the other antitumor agents are not particularly limited. Examples include antimetabolites, antitumor antibiotics, molecular target drugs, platinum-based drugs, and plant alkaloid-based drugs.
  • antimetabolites include 5-fluorouracil (5-FU), 5-fluoro-2’-deoxyuridine (FdUrd), tegafur, combination drugs of tegafur and uracil (e.g., UFT), combination drugs of tegafur, gimeracil, and oteracil (e.g., TS-1), pemetrexed, trifluridine, combination drugs of trifluridine and tipiracil hydrochloride (e.g., Lonsurf), gemcitabine, capecitabine, nelarabine, clofarabine, cytarabine, DNA methylation inhibitors (such as azacitidine, decitabine, cedazuridine and guadecitabine), and the like, with cytarabine or DNA methylation inhibitors, such as azacitidine, decitabine, cedazuridine and guadecitabine, being preferable, and cytarabine, azacitidine, decitabine
  • antitumor antibiotics examples include daunorubicin, doxorubicin, amrubicin, idarubicin, epirubicin, and like anthracycline-based antitumor antibiotics, mitomycin C, bleomycin, and the like, with anthracycline-based antitumor antibiotics being preferable, and daunorubicin being more preferable.
  • molecular target drugs examples include all-trans retinoic acid (ATRA) or derivatives thereof, human MDM2 (mouse double minute 2)(HDM2; human double minute 2) inhibitors, and HDAC inhibitors.
  • ATRA all-trans retinoic acid
  • human MDM2 mouse double minute 2
  • HDM2 human double minute 2
  • HDAC inhibitors HDAC inhibitors
  • the all-trans retinoic acid (ATRA) or a derivative thereof is preferably tretinoin (ATRA) or tamibarotene, and more preferably tretinoin (ATRA).
  • ATRA is administered every day of the 21-day cycle or 28-day cycle with no resting period. In one embodiment, ATRA is administered twice daily.
  • the human MDM2 (HDM2) inhibitor is preferably RG7388 (RO5503781), AMG-232, DS-3032b, RG7112 (RO5045337), SAR405838, MK-8242, or a 1-methoxyisoindoline such as (2S,3S)-3-(4-chlorophenyl)-3-[1 -(4-chlorophenyl)-7-fluoro-5-[(1 S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1 H-isoindol-2-yl]-2-methylpropanoic or (2S,3S)-3-(4-chlorophenyl)-3-[1 -(4-chlorophenyl)-7-fluoro-5-[(1 S)-1 -hydroxy-1 -(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,
  • HDAC inhibitors include vorinostat, panobinostat, romidepsin, belinostat, and the like.
  • the molecular target drug is preferably all-trans retinoic acid (ATRA) or a derivative thereof, a human MDM2 (HDM2) inhibitor, or an HDAC inhibitor, and more preferably tretinoin (ATRA) or RG7388.
  • ATRA all-trans retinoic acid
  • HDM2 human MDM2
  • HDAC HDAC inhibitor
  • platinum-based drugs examples include oxaliplatin, carboplatin, cisplatin, nedaplatin, and the like, with carboplatin or cisplatin being preferable.
  • plant alkaloid-based drugs include microtubule inhibitors, such as paclitaxel, docetaxel, vinblastine, vincristine, vindesine, vinorelbine, and eribulin, and topoisomerase inhibitors, such as irinotecan (SN-38), nogitecan, and etoposide, with taxane microtubule inhibitors such as paclitaxel and docetaxel or topoisomerase inhibitors such as irinotecan (SN-38), nogitecan, and etoposide being preferable, and paclitaxel, irinotecan (SN-38), or etoposide being more preferable.
  • microtubule inhibitors such as paclitaxel, docetaxel, vinblastine, vincristine, vindesine, vinorelbine, and eribulin
  • topoisomerase inhibitors such as irinotecan (SN-38), nogitecan, and etoposide
  • the one or more other antitumor agents are preferably an antimetabolite, an antitumor antibiotic, a molecular target drug, a platinum-based drug, or a plant alkaloid-based drug, more preferably an antimetabolite, an antitumor antibiotic, all-trans retinoic acid (ATRA) or a derivative thereof, a human MDM2 (HDM2) inhibitor, an HDAC inhibitor, a platinum-based drug, or a plant alkaloid-based drug, more preferably an antimetabolite, an antitumor antibiotic, all-trans retinoic acid (ATRA) or a derivative thereof, a human MDM2 (HDM2) inhibitor, a platinum-based drug, or a plant alkaloid-based drug, more preferably an antimetabolite, an antitumor antibiotic, all-trans retinoic acid (ATRA) or a derivative thereof, a human MDM2 (HDM2) inhibitor, a platinum-based drug, or a plant alkaloid-based drug, more preferably an anti
  • the preparations of the one or more other antitumor agents also include drug delivery system (DDS) preparations for them.
  • DDS drug delivery system
  • paclitaxel includes albumin-bound paclitaxel (e.g., Abraxane), paclitaxel micelles (e.g., NK105), and the like
  • cisplatin includes cisplatin micelles (e.g., NC-6004) and the like.
  • the administration schedule of the present invention is also applicable for preventing diseases or disorders characterized by the expression of LSD1. It is also applicable for administration in pre-surgical operation or post-surgical operation, or as an adjuvant therapy or post-adjuvant therapy.
  • a method of preventing and/or treating a disease or disorder characterized by the expression of LSD1 in a patient in need includes administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile, or a salt thereof, to the patient on an administration schedule comprising daily dosing for one week continuously, followed by a resting period of one week.
  • the method described in clause [1] can include an administration schedule based on a 2-week cycle comprising continuous, daily dosing for one week, followed by a resting period of one week, and the cycle is performed once or repeated two or more times.
  • the methods described in clauses [1] or [2] can include administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof once per day for one week.
  • the methods described in clauses [1], [2] or [3] can include orally administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof.
  • Clause [5] in another embodiment, the methods described in clauses [1], [2], [3] or [4] can be used to treat a disease or disorder characterized by a presence of a tumor.
  • Clause [6] in another embodiment, the methods described in clauses [1], [2], [3], [4] or [5] can be used to treat a disease or characterized by a presence of a malignant tumor.
  • the methods described in clauses [1], [2], [3], [4] or [5] can include administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or salt thereof at a daily dose in the range from 10 nanograms to 20 milligrams per kilogram of bodyweight.
  • a method of treating a patient with a disease or disorder characterized by the expression of LSD1 can include administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule comprising continuous, daily dosing for a period of two weeks, followed by a resting period of one week.
  • the method described in clause [8] can include an administration schedule based on a 3-week cycle, with the cycle performed once or repeated two or more times.
  • the methods described in clauses [8] or [9] can include administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof once per day for two weeks.
  • the methods described in clauses [8], [9] or [10] can include orally administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof.
  • Clause [12] in another embodiment, the methods described in clauses [8], [9], [10] or [11] can be used to treat a disease or disorder characterized by a presence of a tumor.
  • Clause [13] in another embodiment, the methods described in clauses [8], [9], [10], [11] or [12] can be used to treat a disease or disorder characterized by a presence of a a malignant tumor.
  • the methods described in clauses [8], [9], [10], [11], [12] or [13] can include administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or salt thereof at a daily dose in the range from 10 nanograms to 20 milligrams per kilogram of bodyweight.
  • a method of treating acute myeloid leukemia (AML) in a patient in need can include comprising administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient as a single agent administered once daily on specific days during a 28-day cycle.
  • the method described in clause [15] can include administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof daily for one week, followed by a resting period of one week.
  • a method of treating acute myeloid leukemia (AML) in a patient in need can include comprising administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient as a single agent administered once daily on specific days during a 21-day cycle.
  • the method described in clause [17] can include administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for two weeks, followed by a resting period of one week.
  • a method of treating acute myeloid leukemia (AML) in a patient in need can administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on specific days during a 28-day cycle, in combination with all-trans retinoic acid (ATRA) twice daily.
  • ATRA all-trans retinoic acid
  • the method described in clause [19] can include administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof daily for one week, followed by a resting period of one week.
  • a method of treating acute myeloid leukemia (AML) in a patient in need can administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on specific days during a 21-day cycle, in combination with all-trans retinoic acid (ATRA) twice daily.
  • ATRA all-trans retinoic acid
  • the method described in clause [21] can include administering a method of treating acute myeloid leukemia (AML) in a patient in need can include administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for two weeks, followed by a resting period of one week.
  • AML acute myeloid leukemia
  • a method of reducing the risk of recurrence of acute myeloid leukemia (AML) or death for a patient diagnosed with AML can include comprising administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule comprising daily dosing for one week, followed by a resting period of one week.
  • a method of reducing the risk of recurrence of acute myeloid leukemia (AML) or death for a patient diagnosed with AML can include administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule comprising daily dosing for two weeks, followed by a resting period of one week.
  • a method of reducing the risk of recurrence of acute myeloid leukemia (AML) or death for a patient diagnosed with AML can include administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule comprising daily dosing for one week, followed by a resting period of one week, in combination with all-trans retinoic acid (ATRA) twice daily.
  • ATRA all-trans retinoic acid
  • a method of reducing the risk of recurrence of acute myeloid leukemia (AML) or death for a patient diagnosed with AML can include administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule comprising daily dosing for two weeks, followed by a resting period of one week, in combination with all-trans retinoic acid (ATRA) twice daily.
  • ATRA all-trans retinoic acid
  • the method described in any one of one of claims 15-18 can reduce the risk of recurrence of AML or death by at least about 5%, at least about 10%, at least about 15%, at least about 20%, or at least about 25%.
  • use of a compound comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof can be for the manufacture of a medicament for treating acute myeloid leukemia (AML), wherein the medicament is prepared to be administered on an administration schedule comprising daily dosing for one week, followed by a resting period of one week.
  • AML acute myeloid leukemia
  • use of a compound comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof can be for the manufacture of a medicament for treating acute myeloid leukemia (AML), wherein the medicament is prepared to be administered on an administration schedule comprising daily dosing for two weeks, followed by a resting period of one week.
  • AML acute myeloid leukemia
  • use of a compound comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof can be for the manufacture of a medicament for treating acute myeloid leukemia (AML), wherein the medicament is prepared to be administered on an administration schedule comprising daily dosing for one week, followed by a resting period of one week, in combination with all-trans retinoic acid (ATRA) twice daily.
  • AML acute myeloid leukemia
  • use of a compound comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof can be for the manufacture of a medicament for treating acute myeloid leukemia (AML), wherein the medicament is prepared to be administered on an administration schedule comprising daily dosing for two weeks, followed by a resting period of one week, in combination with all-trans retinoic acid (ATRA) twice daily.
  • AML acute myeloid leukemia
  • aspects of the invention include a pharmaceutical composition for preventing and/or treating a disease or disorder characterized by the expression of LSD1 in a patient in need, wherein the pharmaceutical composition comprises 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof, and is administered to the patient on an administration schedule comprising continuous, daily dosing for one week, followed by a resting period of one week.
  • the pharmaceutical composition described in clause [32] can include a pharmaceutical carrier.
  • compositions described in clauses [32] or [33] can be administered on an administration schedule based on a 2-week cycle, with the cycle performed once or repeated two or more times.
  • compositions described in clauses [32], [33] or [34] can be administered once per day for one week.
  • compositions described in clauses [32], [33], [34] or [35] can be oral compositions.
  • compositions described in clauses [32], [33], [34], [35] or [36] can be used to treat a disease or disorder characterized by a presence of a tumor.
  • compositions described in clauses [32], [33], [34], [35], [36] or [37] can be used to treat a disease or disorder characterized by a presence of a malignant tumor.
  • compositions described in clauses [32], [33], [34], [35], [36], [37] or [38] can be administered at a daily dose in the range from 10 nanograms to 20 milligrams per kilogram of bodyweight.
  • aspects of the invention include a pharmaceutical composition for treating a disease or disorder characterized by the expression of LSD1 in a patient in need, wherein the pharmaceutical composition comprises 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof, and the pharmaceutical composition can be administered to the patient on an administration schedule comprising continuous, daily dosing for two weeks, followed by a resting period of one week.
  • the pharmaceutical composition described in clause [40] can further include a pharmaceutical carrier.
  • compositions described in clauses [40] or [41] can be administered on an administration schedule based on a 3-week cycle, with the cycle performed once or repeated two or more times.
  • compositions described in clauses [40], [41] or [42] can be administered once per day for one week.
  • compositions described in clauses [40], [41], [42] or [43] can be oral compositions.
  • compositions described in clauses [40], [41], [42], [43] or [44] can be used to treat a disease or disorder characterized by a presence of a tumor.
  • compositions described in clauses [40], [41], [42], [43], [44] or [45] can be used to treat a disease or disorder characterized by a presence of a malignant tumor.
  • compositions described in clauses [40], [41], [42], [43], [44], [45] or [46] can be administered at a daily dose in the range from 10 nanograms to 20 milligrams per kilogram of bodyweight.
  • a process for preparing a medicament for the prevention or treatment of a disease or disorder characterized by the expression of LSD1 includes preparing a composition comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof, wherein the medicament is administered to the patient on an administration schedule comprising continuous, daily dosing for one week, followed by a resting period of one week.
  • a process for preparing a medicament can include preparing a composition described in clause [48] that can be administered on an administration schedule based on a 2-week cycle, with the cycle performed once or repeated two or more times.
  • a process for preparing a medicament includes preparing a composition described in clauses [48] or [49] that can include 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for administration once per day for one week.
  • a process for preparing a medicament includes preparing a composition described in clauses [48], [49] or [50] that can include 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for oral administration.
  • a process for preparing a medicament includes preparing a composition described in clauses [48], [49], [50] or [51] for use in treating a disease or disorder characterized by a presence of a tumor.
  • a process for preparing a medicament includes preparing a composition described in clauses [48], [49], [50], [51] or [52] for use in treating a disease or disorder characterized by a presence of a malignant tumor.
  • a process for preparing a medicament includes preparing a composition described in clauses [48], [49], [50], [51] or [52] that can include 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for administration at a daily dose in the range from 10 nanograms to 20 milligrams per kilogram of bodyweight.
  • a method of treating a disease or disorder characterized by the expression of LSD1 includes administering to a patient in need an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule comprising continuous, daily dosing for two weeks, followed by a resting period of one week.
  • a method of treating a disease or disorder characterized by the expression of LSD1 described in clause [55] can include administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule based on a 3-week cycle, with the cycle performed once or repeated two or more times.
  • a method of treating a disease or disorder characterized by the expression of LSD1 described in clauses [55] or [56] can include administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof once per day for two weeks.
  • a method of treating a disease or disorder characterized by the expression of LSD1 described in clauses [55], [56] or [57] can include orally administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof.
  • a method of treating a disease or disorder characterized by the expression of LSD1 described in clauses [55], [56], [57] or [58] can include treating a disease or disorder characterized by a presence of a tumor.
  • a method of treating a disease or disorder characterized by the expression of LSD1 described in clauses [55], [56], [57], [58] or [59] can include treating a disease or disorder characterized by a presence of a malignant tumor.
  • a method of treating a disease or disorder characterized by the expression of LSD1 described in clauses [55], [56], [57], [58], [59] or [60] can include administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof at a daily dose in the range from 10 nanograms to 20 milligrams per kilogram of bodyweight.
  • hydrochloride of Compound A in the Reference Example 1, hydrochloride of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile) was used, and this compound is referred to as “Test Compound A” for convenience) induced severe thrombocytopenia and neutropenia in rats, dogs and monkeys (data not shown). However, those toxicities were recovered after cessation of dosing.
  • Test Compound A was evaluated in 6-week old male Crl:CD(SD) rats (Charles River Laboratories Japan, Inc.) administered Test Compound A orally.
  • pre-test group (1-week ON+1-week OFF dosing regimen)
  • one cycle of administration of Test Compound A was performed.
  • Group I (1-week ON+1-week OFF dosing regimen)
  • two cycles of administration of Test Compound A were performed, with each cycle consisting of a dosing period of 7 consecutive days (1 week) once daily and a resting period of 7 days (1 week).
  • Test Compound A was administered continuously once daily for 14 days (2 weeks) and a resting period for 7 days (1 week). The resting period is a no-dosing period for recovery. Test Compound A was suspended in 5 mg/mL hypromellose solution. In the case of control, the vehicle without Test Compound A was administered to the animals.
  • Test Compound A was administered at doses of 0 mg/kg (vehicle as control), 4 mg/kg (only for the pre-test group) and 16 mg/kg (for Group I and Group II) each at a dose volume of 5 mL/kg. For all rats, hematological evaluation and bone marrow smear examination were conducted. For the pre-test group, samples were collected on Days 8 and 15. For Group I, samples were collected on Days 8, 15, 22 and 29 for Test Compound A-treated animals, and on Days 8 and 29 for vehicle-treated animals. For Group II, samples were collected on Days 15 and 22 for both Test Compound A-treated animals and vehicle-treated animals.
  • each rat was laparotomized under isoflurane anesthesia and blood was collected via the posterior vena cava using a disposable syringe with a needle.
  • the collected blood was dispensed as a volume of approximately 1 mL into a container containing EDTA-2K for conducting the hematological tests using ADVIA2120i Multi-Species hematology system.
  • necropsy was conducted and bone marrow was collected from rats. Bone marrow liquid was collected and mixed with rat plasma, and used for making smear slide with Wedge-method.
  • Bone marrow smear samples were stained with May-Grunwald Giemsa staining and were subjected to light microscopy. Approximately 200 cells (differential count) of all cells were counted in each of different microscopic fields to maintain representative ratios of cell types.
  • FIGS. 1A, 1B, 2A and 2B illustrate results of hematology analysis of peripheral blood samples.
  • rats of Group I treated with 16 mg/kg of Test Compound A showed decreases in platelets and neutrophils after 1-week (FIG. 1A (platelets) and FIG. 1B (neutrophils), “1 week” column, right filled bar) .
  • Rats of Group II treated with 16 mg/kg of Test Compound A also showed decreases in platelets and neutrophils after 2-week (FIG. 2A (platelets) and FIG. 2B (neutrophils), “2 week” column, right filled bar).
  • FIGS. 3, 4A and 4B illustrate results of smear analysis of bone marrow.
  • myeloblasts, other progenitor cells and stem cells were not affected by treatment with Test Compound A.
  • Neutrophil-lineage cells such as myelocytes, metamyelocytes and mature neutrophils, were decreased at end of the dosing period (1-week or 2-week) (data not shown).
  • abnormal shaped neutrophil-lineage myelocytes appeared (FIG. 3).
  • promyelocytes in neutrophil-lineage were increased at the same period.
  • myelocyte-lineages such as eosinophil- and basophil-lineages.
  • Test Compound A affected bone marrow differentiation step from promyelocytes to myelocytes in the neutrophil-lineage. Additionally, in platelet-lineage, normal megakaryocytes were severely decreased and vulnerable or morphological abnormal megakaryocytes (FIGS. 4A and 4B) were markedly increased at the end of dosing period (data not shown). After 1-week cessation of dosing, neutrophil-lineage cells, especially mature neutrophils, were markedly increased and abnormal megakaryocytes disappeared.
  • Test Compound A induced myelosuppression in rats and affected bone marrow differentiation steps of neutrophil- and platelet-lineages.
  • Test Compound A did not affect hematopoietic stem cells, progenitors and myeloblasts. Therefore, those myelosuppression effects disappeared after cessation of dosing for 1-week.
  • intermittent dosing regimen with a cessation period (at least 1-week) is important for Test Compound A to manage and control myelosuppression which is induced by continuous dosing of Test Compound A.
  • mice were assigned to groups so that the average TV of each group was equivalent.
  • Test Compound A was prepared as follows: 0 mg/kg/day (vehicle without the compound), 100 mg/kg/day and 150mg/kg/day.
  • the compound was orally administered once daily for 3 weeks at 0 mg/kg/day (Control), consecutively once daily for 3 weeks at 100 mg/kg/day (Continuous group: 3-week ON regimen), once daily for 7 consecutive days (1 week) at 150 mg/kg/day followed by a resting period of 7 days (1 week) followed by 7 consecutive days (1 week) at 150 mg/kg/day (Group I: 1-week ON + 1-week OFF regimen), and once daily for 2 weeks at 100 mg/kg/day followed by a resting period of 7 days (1 week) (Group II: 2-week ON + 1-week OFF regimen), from Day 1.
  • the dosages of Compound A are maximum tolerated doses (MTD) of each dosing schedule.
  • the evaluation period was set to 21 days, and the last evaluation day was set to Day 22.
  • the body weight (BW) was sequentially measured, and the average body weight change [BWC (%)] relative to the body weight on Day 0 was calculated until the last evaluation day by the following formula (n: day of body weight measurement performed twice a week; the last measurement day corresponds to Day 22, which is the last evaluation day).
  • FIG. 6 shows the results.
  • BWC (%) [(BW on Day n) - (BW on Day 0)] / (BW on Day 0) x 100
  • FIG. 5 shows the antitumor effects. Compared with Day 0, regression of mean TV value was observed at Day 22 in Continuous group, Group I group, and Group II group, while mean TV was increased more than 4 fold during the dosing period in Control group. The mean TV values of all the groups except for the Control group were comparable during the dosing period.
  • FIG. 6 shows the body weight changes.
  • body weight loss was observed in Continuous group.
  • intermittent dosing groups such as Group I group and Group II group, did not show any body weight reduction at Day 22. Therefore, intermittent dosing schedules, such as 1-week ON + 1-week OFF regimen and 2-week ON + 1-week OFF, improved the body weight reduction over the continuous daily dosing regimen (3-week ON).
  • Test Compound A with intermittent dosing schedules, such as 1-week ON + 1-week OFF regimen and 2-week ON + 1-week OFF regimen, is sufficiently expected to become a very useful method that exhibits antitumor effects while avoiding toxicity resulting from administration of the compound in clinical treatment.
  • Reference Example 3 A Study of Test Compound A With All-Trans Retinoic Acid in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
  • Test Compound A administered as a single agent and in combination with all-trans retinoic acid (ATRA) in participants with acute myeloid leukemia (AML) who have relapsed or are refractory (r/r) to prior treatment.
  • ATRA all-trans retinoic acid
  • the study duration is expected to be approximately 30 months.
  • Safety Number of participants with treatment-emergent adverse events (TEAEs) [Time Frame: Approximately 30 months]
  • Pharmacokinetic parameter Area under the curve (AUC) [Time Frame: Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)]
  • a. is refractory to standard induction chemotherapy, including but not limited to anthracycline and cytarabine combination therapy, or
  • b. has relapsed after anthracycline and cytarabine therapy or stem cell transplant (SCT), or
  • c. is refractory to or has relapsed after a front-line regimen containing a hypomethylating agent, alone or in combination.
  • AST aspartate aminotransferase
  • ALT alanine aminotransferase
  • M3 AML or APML or APL Diagnosis of acute promyelocytic leukemia
  • Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
  • prednisone more than 5 mg/day (Note: Prednisone at any dose for other indications is allowed).
  • HIV human immunodeficiency virus
  • HBV hepatitis B virus
  • HCV hepatitis C virus
  • Inactive hepatitis carrier status or low viral hepatitis titer being treated with antivirals is allowed.
  • serologies should be used to establish negativity.
  • Non-AML-associated pulmonary disease requiring >2 liters per minute (LPM) oxygen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé de traitement d'une maladie ou d'un trouble lié à LSD1 chez un patient en ayant besoin, le procédé comprenant l'administration d'une quantité efficace de 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-méthyl-propyl)phényl]phényl]-2-fluoro-benzonitrile ou d'un sel de celui-ci au patient sur la base d'un programme d'administration comprenant un dosage quotidien pendant une semaine ou deux semaines, suivi d'une période de repos d'une semaine.
PCT/JP2020/042410 2019-11-13 2020-11-13 Procédés de traitement de maladies et de troubles associés à lsd1 avec des inhibiteurs de lsd1 Ceased WO2021095840A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2022527859A JP7492002B2 (ja) 2019-11-13 2020-11-13 Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法
MX2022005812A MX2022005812A (es) 2019-11-13 2020-11-13 Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina.
KR1020227019783A KR20220113390A (ko) 2019-11-13 2020-11-13 Lsd1 억제제를 사용하여 lsd1-관련 질환 및 장애를 치료하는 방법
EP20886658.2A EP4058018A4 (fr) 2019-11-13 2020-11-13 Procédés de traitement de maladies et de troubles associés à lsd1 avec des inhibiteurs de lsd1
BR112022008020A BR112022008020A2 (pt) 2019-11-13 2020-11-13 Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
CA3158442A CA3158442A1 (fr) 2019-11-13 2020-11-13 Procedes de traitement de maladies et de troubles associes a lsd1 avec des inhibiteurs de lsd1
AU2020382379A AU2020382379B2 (en) 2019-11-13 2020-11-13 Methods of treating LSD1-related diseases and disorders with LSD1 inhibitors
CN202080079021.0A CN114828844A (zh) 2019-11-13 2020-11-13 用lsd1抑制剂治疗lsd1相关疾病和病症的方法
PH1/2022/551169A PH12022551169A1 (en) 2019-11-13 2020-11-13 METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS
US17/775,800 US20220387384A1 (en) 2019-11-13 2020-11-13 Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962934923P 2019-11-13 2019-11-13
US62/934,923 2019-11-13

Publications (1)

Publication Number Publication Date
WO2021095840A1 true WO2021095840A1 (fr) 2021-05-20

Family

ID=75912767

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2020/042383 Ceased WO2021095835A1 (fr) 2019-11-13 2020-11-13 Nouveau sel de composé terphényle
PCT/JP2020/042410 Ceased WO2021095840A1 (fr) 2019-11-13 2020-11-13 Procédés de traitement de maladies et de troubles associés à lsd1 avec des inhibiteurs de lsd1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/042383 Ceased WO2021095835A1 (fr) 2019-11-13 2020-11-13 Nouveau sel de composé terphényle

Country Status (18)

Country Link
US (2) US12419858B2 (fr)
EP (2) EP4058151B1 (fr)
JP (2) JP7379680B2 (fr)
KR (2) KR102825246B1 (fr)
CN (2) CN114828844A (fr)
AU (2) AU2020382379B2 (fr)
BR (2) BR112022009221A2 (fr)
CA (2) CA3157404A1 (fr)
DK (1) DK4058151T3 (fr)
ES (1) ES3034158T3 (fr)
FI (1) FI4058151T3 (fr)
HU (1) HUE072206T2 (fr)
MX (2) MX2022005812A (fr)
PH (2) PH12022551137A1 (fr)
PL (1) PL4058151T3 (fr)
PT (1) PT4058151T (fr)
TW (2) TWI874489B (fr)
WO (2) WO2021095835A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240886A1 (fr) * 2021-05-11 2022-11-17 Astex Pharmaceuticals, Inc. Formes solides de sels de 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-éthylpropyl)phényl]phényl]-2-fluoro-benzonitrile
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
EP4408417A4 (fr) * 2021-09-30 2025-08-06 Taiho Pharmaceutical Co Ltd Polythérapie pour le cancer à l'aide d'un composé de biphényle et d'un régulateur de molécule de point de contrôle immunitaire
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018221555A1 (fr) 2017-05-31 2018-12-06 大鵬薬品工業株式会社 Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1
CA3157404A1 (fr) 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. Nouveau sel de compose terphenyle
WO2022214303A1 (fr) 2021-04-08 2022-10-13 Oryzon Genomics, S.A. Combinaisons d'inhibiteurs de lsd1 pour le traitement de cancers myéloïdes
CN118510763A (zh) * 2021-10-26 2024-08-16 阿斯泰克斯制药公司 1-(3-氨基吡咯烷-1-羰基)-3,4-二苯基苯化合物的苯甲酸盐的制备方法
EP4522137A1 (fr) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Méthodes de traitement de tumeurs mutantes nf1 à l'aide d'inhibiteurs de lsd1
EP4522136A1 (fr) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Méthodes de traitement d'une tumeur maligne des gaines des nerfs périphériques (tmgnp) à l'aide d'inhibiteurs de lsd1
KR20250109775A (ko) 2022-11-24 2025-07-17 오리존 지노믹스 에스.에이. 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합
WO2024229073A1 (fr) * 2023-05-02 2024-11-07 Otsuka Pharmaceutical Co., Ltd. Dosage basé sur la réponse pour le traitement du cancer avec un agent d'hypométhylation et de la cedazuridine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017090756A1 (fr) * 2015-11-27 2017-06-01 大鵬薬品工業株式会社 Nouveau composé de biphényle ou un sel de celui-ci
WO2018216795A1 (fr) * 2017-05-26 2018-11-29 大鵬薬品工業株式会社 Potentialisateur d'effet antitumoral utilisant un nouveau composé biphényle
WO2018216800A1 (fr) * 2017-05-26 2018-11-29 大鵬薬品工業株式会社 Nouveau composé de biphényle ou sel de celui-ci
WO2018221555A1 (fr) * 2017-05-31 2018-12-06 大鵬薬品工業株式会社 Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801518D0 (sv) * 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
US6225049B1 (en) 1992-06-17 2001-05-01 The United States Of America As Represented By The Department Of Health And Human Services Human insulinoma-associated cDNA
CA2469649C (fr) 2001-12-13 2011-05-03 Natrogen Therapeutics, Inc. Derives d'isoindigo, d'indigo et d'indirubine et utilisation de ceux-ci dans le traitement de cancer
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
EP1792622A1 (fr) 2005-11-11 2007-06-06 GPC Biotech AG Thérapie combinée antiproliférative comprenant un agent chimiothérapeutique à base de platine et d'inhibiteurs EGFR ou d'analogues de la pyrimidine
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
US8163509B2 (en) 2008-10-20 2012-04-24 The Regents Of The University Of Colorado, A Body Corporate Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2010077624A1 (fr) 2008-12-09 2010-07-08 Merck Sharp & Dohme Corp. Biaryl carboxamides
EP2419177A1 (fr) 2009-04-17 2012-02-22 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de récepteur kinase de facteur de croissance épidermique
EP2560949B1 (fr) 2010-04-20 2015-12-02 Università degli Studi di Roma "La Sapienza" Dérivés de tranylcypromine comme inhibiteurs de l'histone déméthylase lsd1 et/ou lsd2
CN104892525A (zh) 2010-07-29 2015-09-09 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
ES2642170T3 (es) 2011-05-16 2017-11-15 Taiho Pharmaceutical Co., Ltd. Método para seleccionar la quimioterapia para un paciente con cáncer gástrico utilizando combinación de fármacos de tegafur, gimeracilo y oteracilo potásico e inhibidor de EGFR
EP2768805B1 (fr) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. Composés (hétéro)aryl cyclopropyl comme inhibiteurs de lsd1
MX370567B (es) * 2012-05-09 2019-12-17 Cantex Pharmaceuticals Inc Tratamiento de mielosupresion.
EP2968358A4 (fr) 2013-03-15 2016-08-10 Ariad Pharma Inc Nouveaux inhibiteurs de choline kinase
DK3030323T3 (da) 2013-08-06 2019-07-15 Imago Biosciences Inc Kdm1a-inhibitorer til behandlingen af sygdom
US9266907B2 (en) 2013-09-05 2016-02-23 King Abdullah University Of Science And Technology Tunable rare-earth fcu-metal-organic frameworks
DK3080100T3 (da) 2013-12-11 2023-02-06 Celgene Quanticel Res Inc Hæmmere af lysinspecifik demethylase-1
CA2936111C (fr) 2014-01-06 2023-03-14 Algomedix, Inc. Modulateurs de trpa1
CN106659914B (zh) 2014-05-01 2020-06-19 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶-1的抑制剂
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
CA2958704A1 (fr) 2014-08-25 2016-03-03 University Of Canberra Compositions pour moduler les cellules souches cancereuses et leurs utilisations
SG10202008486SA (en) 2014-09-05 2020-09-29 Celgene Quanticel Research Inc Inhibitors of lysine specific demethylase-1
WO2016172010A1 (fr) 2015-04-20 2016-10-27 Effector Therapeutics, Inc. Inhibiteurs de modulateurs de points de contrôle immunitaire destinés à être utilisés dans le traitement du cancer et d'infections
WO2017013061A1 (fr) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarqueurs associés à des inhibiteurs de lsd1 et utilisations de ceux-ci
WO2018136961A1 (fr) 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. Méthodes de traitement de patients à l'aide d'un agoniste du récepteur alpha de l'acide rétinoïque et d'un anticorps anti-cd38
HRP20230210T1 (hr) 2017-06-30 2023-04-14 Celgene Corporation Pripravci i postupci upotrebe 2-(4-klorofenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoroacetamida
WO2019075327A1 (fr) 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. Traitement du carcinome à cellules de merkel
WO2019083971A1 (fr) 2017-10-23 2019-05-02 Children's Medical Center Corporation Méthodes de traitement du cancer à l'aide d'inhibiteurs de lsd1 en combinaison avec une immunothérapie
AU2018377852B2 (en) 2017-11-29 2022-03-24 Epiaxis Therapeutics Pty Ltd Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist
EP3735243A4 (fr) 2018-01-02 2021-08-25 Celgene Corporation Isotopologues de 2-(4-chlorophényl)-n-((2-(2,6-dioxopipéridin-3-yl)-1-oxoisoindolin-5-yl)méthyl)-2,2-difluoroacétamide
BR112022000484A2 (pt) 2019-07-17 2022-03-08 Summit Oxford Ltd Processo de preparação de ridinilazol e formas cristalinas do mesmo
CA3157404A1 (fr) 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. Nouveau sel de compose terphenyle
KR20220151637A (ko) 2020-03-06 2022-11-15 셀젠 콴티셀 리서치, 인크. Sclc 또는 sqnsclc를 치료하는데 사용하기 위한 lsd-1 억제제 및 니볼루맙의 조합

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017090756A1 (fr) * 2015-11-27 2017-06-01 大鵬薬品工業株式会社 Nouveau composé de biphényle ou un sel de celui-ci
WO2018216795A1 (fr) * 2017-05-26 2018-11-29 大鵬薬品工業株式会社 Potentialisateur d'effet antitumoral utilisant un nouveau composé biphényle
WO2018216800A1 (fr) * 2017-05-26 2018-11-29 大鵬薬品工業株式会社 Nouveau composé de biphényle ou sel de celui-ci
WO2018221555A1 (fr) * 2017-05-31 2018-12-06 大鵬薬品工業株式会社 Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)", CLINICALTRIALS.GOV, 9 November 2016 (2016-11-09), XP055812339, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/show/NCT02959437> *
DATABASE EMBASE 10 June 2010 (2010-06-10), ANONYMOUS: "Update of cytogenetic and molecular response in 88 elderly ph+ chronic myeloid Leukemia patients enrolled in the phase II explorative study of intermittent imatinib (IM) treatment (interim)", XP055812593, retrieved from STN Database accession no. 0050300062 *
K.N. CHI ET AL.: "A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)", ANNALS OF ONCOLOGY, KLUWER DORDRECHT, NL, vol. 30, no. 5, 1 October 2019 (2019-10-01), NL, pages 897TIP, XP009527851, ISSN: 0923-7534 *
NORIO ASOU: "Recent Advances Science and Care of Leukemia (II), 74 (extra number 10 (1112)", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 74, no. Suppl. 10, 20 December 2016 (2016-12-20), JP, pages 100 - 104, XP009528133, ISSN: 0047-1852 *
RUSSO D, REGAZZI M, SACCHI S, VISANI G, LAZZARINO M, AVVISATI G, PELICCI PG, DASTOLI G, GRANDI C, IACONA I, CANDONI A, GRATTONI R,: "All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase", LEUKEMIA, STOCKTON PRESS, LONDON, vol. 12, no. 4, 1 April 1998 (1998-04-01), London, pages 449 - 454, XP055812337, ISSN: 0887-6924, DOI: 10.1038/sj.leu.2400988 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240886A1 (fr) * 2021-05-11 2022-11-17 Astex Pharmaceuticals, Inc. Formes solides de sels de 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-éthylpropyl)phényl]phényl]-2-fluoro-benzonitrile
EP4408417A4 (fr) * 2021-09-30 2025-08-06 Taiho Pharmaceutical Co Ltd Polythérapie pour le cancer à l'aide d'un composé de biphényle et d'un régulateur de molécule de point de contrôle immunitaire
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras

Also Published As

Publication number Publication date
US20220411368A1 (en) 2022-12-29
TW202128616A (zh) 2021-08-01
US12419858B2 (en) 2025-09-23
KR20220101145A (ko) 2022-07-19
DK4058151T3 (da) 2025-06-30
EP4058018A1 (fr) 2022-09-21
PT4058151T (pt) 2025-06-12
FI4058151T3 (fi) 2025-07-16
PL4058151T3 (pl) 2025-08-04
JP7379680B2 (ja) 2023-11-14
EP4058018A4 (fr) 2023-06-21
PH12022551169A1 (en) 2024-02-19
JP2022550374A (ja) 2022-12-01
EP4058151A1 (fr) 2022-09-21
MX2022005812A (es) 2022-08-16
EP4058151B1 (fr) 2025-05-21
MX2022005811A (es) 2022-06-08
CN114728899B (zh) 2023-12-05
PH12022551137A1 (en) 2023-10-09
TWI874489B (zh) 2025-03-01
TWI874490B (zh) 2025-03-01
AU2020382379A1 (en) 2022-05-05
AU2020382379B2 (en) 2024-03-28
BR112022008020A2 (pt) 2022-07-12
JP7492002B2 (ja) 2024-05-28
AU2020382214B2 (en) 2023-07-06
BR112022009221A2 (pt) 2022-07-26
AU2020382214A1 (en) 2022-04-21
CN114828844A (zh) 2022-07-29
JP2023501627A (ja) 2023-01-18
KR102825246B1 (ko) 2025-06-25
ES3034158T3 (en) 2025-08-13
CA3158442A1 (fr) 2021-05-20
WO2021095835A1 (fr) 2021-05-20
HUE072206T2 (hu) 2025-10-28
EP4058151A4 (fr) 2023-10-25
KR20220113390A (ko) 2022-08-12
CN114728899A (zh) 2022-07-08
TW202128617A (zh) 2021-08-01
US20220387384A1 (en) 2022-12-08
CA3157404A1 (fr) 2021-05-20

Similar Documents

Publication Publication Date Title
AU2020382379B2 (en) Methods of treating LSD1-related diseases and disorders with LSD1 inhibitors
TWI334350B (en) Cancer treatment
EP2154971B1 (fr) Combinaison pharmaceutique synergique pour le traitement du cancer
DK2799070T3 (en) EFFECTIVE AMPLIFIER FOR ANTITUMUM AGENTS
US20230398119A1 (en) Combination therapy involving diaryl macrocyclic compounds
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
US11524009B2 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use
RU2668125C2 (ru) Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
CA2459822C (fr) Traitement de la leucemie myeloide chronique, resistante ou intolerante au sti571, impliquant l&#39;homoharringtonine seul ou en combinaison avec d&#39;autres agents
JP2023080357A (ja) リンパ球悪性疾患を治療するための方法
US8349792B2 (en) Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
US20100226919A1 (en) Antitumoral Treatments
RU2826217C1 (ru) Способы лечения заболеваний и нарушений, связанных с lsd1, ингибиторами lsd1
HK40078096A (en) Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
WO2025214358A1 (fr) Médicament pour le traitement du cancer du pancréas et utilisation associée
US11179349B2 (en) Use of tumor gene methylation regulator and anti-tumor drugs
CN116940365A (zh) 慢性髓性白血病干细胞抑制剂
HK1067562B (en) Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
WO2011152515A1 (fr) Agent anti-tumoral contenant un composé indole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20886658

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020382379

Country of ref document: AU

Date of ref document: 20201113

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022008020

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022527859

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3158442

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020886658

Country of ref document: EP

Effective date: 20220613

ENP Entry into the national phase

Ref document number: 112022008020

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220427